A Phase 2 interventional study of placebo and denosumab in Rheumatoid Arthritis, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Arthritis, Rheumatoid by Amgen — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Amgen.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, this one is the 18th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2004, is one of 14 in phase 2, and was the 4th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 57 studies in Arthritis, Rheumatoid by Amgen is open now, in 10 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–75
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 17 · Phase 4 12
First in 1997; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 211 across the 47 interventional studies, 2,522 across the 4 observational. Of the 56 that completed or were terminated, 30 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Arthritis, Rheumatoid by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
Drug: denosumab
Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
Drug: denosumab
Participants received placebo subcutaneous injections on Day 1 and at Month 6.
Drug: placebo
placebo subcutaneous injection
For subcutaneous injection
Also known as: AMG 162
Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6
Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism \[EULAR\]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).
Time frame: Baseline, Month 6
Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12
TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).
Time frame: Baseline, Month 12
Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6
TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).
Time frame: Baseline, Month 6
Change From Baseline in Radiographic Erosion Score at Month 12
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.
Time frame: Baseline, Month 12
Change From Baseline in Radiographic Erosion Score at Month 6
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.
Time frame: Baseline, Month 6
Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12
Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.
Time frame: Baseline, Month 12
Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6
Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.
Time frame: Baseline, Month 6
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 1
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, month 6
Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 12
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 1
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 6
Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 12
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 1
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 6
Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
Time frame: Baseline, Month 12
Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3
Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 3
Percent Change From Baseline in Serum CTX at Month 6
Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 6
Percent Change From Baseline in Serum CTX at Month 12
Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 12
Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3
Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 3
Percent Change From Baseline in P1NP at Month 6
Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 6
Percent Change From Baseline in P1NP at Month 12
Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 12
Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3
Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 3
Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6
Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 6
Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12
Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
Time frame: Baseline, Month 12
Number of Participants With Anti-Denosumab Binding Antibodies
Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.
Time frame: Assessed at Baseline and at Months 1, 3, 6 and 12.
Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody
Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.
Time frame: Baseline to Month 12
Change From Baseline in Albumin at Month 1
Laboratory Chemistry Albumin
Time frame: Baseline, month 1
Change From Baseline in Albumin at Month 3
Laboratory chemistry albumin
Time frame: Baseline, month 3
Change From Baseline in Albumin at Month 6
Laboratory chemistry albumin
Time frame: Baseline, month 6
Change From Baseline in Albumin at Month 12
Laboratory chemistry albumin
Time frame: Baseline, month 12
Change From Baseline in Alkaline Phosphatase at Month 1
Laboratory chemistry alkaline phoshatatse
Time frame: Baseline, month 1
Change From Baseline in Alkaline Phosphatase at Month 3
Laboratory chemisrty alkaline phosphatase
Time frame: baseline, month 3
Change From Baseline in Alkaline Phosphatase at Month 6
Laboratory chemistry alkaline phosphatase
Time frame: baseline, month 6
Change From Baseline in Alkaline Phosphatase at Month 12
Laboratory chemistry alkaline phosphatase
Time frame: baseine, month 12
Change From Baseline in Bicarbonate at Month 1
Laboratory chemistry bicarbonate
Time frame: baseline, month 1
Change From Baseline in Bicarbonate at Month 3
Laboratory chemistry bicarbonate
Time frame: baseline, month 3
Change From Baseline in Bicarbonate at Month 6
Laboratory chemistry bicarbonate
Time frame: Baseline, month 6
Change From Baseline in Bicarbonate at Month 12
Laboratory chemistry bicarbonate
Time frame: Baseline, Month 12
Change From Baseline in Total Bilirubin at Month 1
Laboratory chemistry total bilirubin
Time frame: baseline, month 1
Change From Baseline in Total Bilirubin at Month 3
Laboratory chemistry total bilirubin
Time frame: Baseline, month 3
Change From Baseline in Total Bilirubin at Month 6
Laboratory chemistry total bilirubin
Time frame: Baseline, month 6
Change From Baseline in Total Bilirubin at Month 12
Laboratory chemistry total bilirubin
Time frame: Baseline, month 12
Change From Baseline in Blood Urea Nitrogen at Month 1
Laboratory chemistry blood urea nitrogen
Time frame: Baseline, month 1
Change From Baseline in Blood Urea Nitrogen at Month 3
Laboratory chemistry blood urea nitrogen
Time frame: Baseline, month 3
Change From Baseline in Blood Urea Nitrogen at Month 6
Laboratory chemistry blood urea nitrogen
Time frame: Baseline, month 6
Change From Baseline in Blood Urea Nitrogen at Month 12
Laboratory chemistry blood urea nitrogen
Time frame: baseline, month 12
Change From Baseline in Calcium at Month 1
Laboratory chemistry calcium
Time frame: baseline. month 1
Change From Baseline in Calcium at Month 3
Laboratory chemistry calcium
Time frame: Baseline, month 3
Change From Baseline in Calcium at Month 6
Laboratory chemistry calcium
Time frame: baseline, month 6
Change From Baseline in Calcium at Month 12
Laboratory chemistry calcium
Time frame: Baseline, month 12
Change From Baseline in Calcium (Corrected) at Month 1
Laboratory chemistry albumin-adjusted calcium
Time frame: Baseline, month 1
Change From Baseline in Calcium (Corrected) at Month 3
Laboratory chemistry albumin-adjusted calcium
Time frame: baseline, month 3
Change From Baseline in Calcium (Corrected) at Month 6
Laboratory chemistry albumin-adjusted calcium
Time frame: Baseline, Month 6
Change From Baseline in Calcium (Corrected) at Month 12
Laboratory chemistry albumin-adjusted calcium
Time frame: Baselien, Month 12
Change From Baseline in Chloride at Month 1
Laboratory chemistry chloride
Time frame: baseline, month 1
Change From Baseline in Chloride at Month 3
Laboratory chemistry chloride
Time frame: Baseline, month 3
Change From Baseline in Chloride at Month 6
Laboratory chemistry chloride
Time frame: Baseline, month 6
Change From Baseline in Chloride at Month 12
Laboratory chemistry chloride
Time frame: Baseline, month 12
Change From Baseline in Creatinine at Month 1
Laboratory chemistry creatinine
Time frame: Baseline, month 1
Change From Baseline in Creatinine at Month 3
Laboratory chemistry creatinine
Time frame: Baseline, month 3
Change From Baseline in Creatinine at Month 6
Laboratory chemistry creatinine
Time frame: Baseline, month 6
Change From Baseline in Creatinine at Month 12
Laboratory chemistry creatinine
Time frame: Baseline, month 12
Change From Baseline in Gamma-Glutamyl Transferase at Month 1
Laboratory chemistry gamma-glutamyl transferase
Time frame: Baseline, month 1
Change From Baseline in Gamma-Glutamyl Transferase at Month 3
Laboratory chemistry gamma-glutamyl transferase
Time frame: Baseline, month 3
Change From Baseline in Gamma-Glutamyl Transferase at Month 6
Laboratory chemistry gamma-glutamyl transferase
Time frame: Baseline, month 6
Change From Baseline in Gamma-Glutamyl Transferase at Month 12
Laboratory chemistry gamma-glutamyl transferase
Time frame: Baseline, month 12
Change From Baseline in Glucose at Month 1
Laboratory chemistry glucose
Time frame: Baseline, month 1
Change From Baseline in Glucose at Month 3
Laboratory chemistry glucose
Time frame: Baseline, month 3
Change From Baseline in Glucose at Month 6
Laboratory chemistry glucose
Time frame: Baseline, month 6
Change From Baseline in Glucose at Month 12
Laboratory chemistry glucose
Time frame: baseline, month 12
Change From Baseline in Potassium at Month 1
Laboratory chemistry potassium
Time frame: Baseline, month 1
Change From Baseline in Potassium at Month 3
Laboratory chemistry potassium
Time frame: Baseline, month 3
Change From Baseline in Potassium at Month 6
Laboratory chemistry potassium
Time frame: Baseline, month 6
Change From Baseline in Potassium at Month 12
Laboratory chemistry potassium
Time frame: Baseline, month 12
Change From Baseline in Magnesium at Month 1
Laboratory chemistry magnesium
Time frame: Baseline, month 1
Change From Baseline in Magnesium at Month 3
Laboratory chemistry magnesium
Time frame: Baseline, month 3
Change From Baseline in Magnesium at Month 6
Laboratory chemistry magnesium
Time frame: Baseline, month 6
Change From Baseline in Magnesium at Month 12
Laboratory chemistry magnesium
Time frame: Baseline, month 12
Change From Baseline in Sodium at Month 1
Laboratory chemistry sodium
Time frame: Baseline, month 1
Change From Baseline in Sodium at Month 3
Change From Baseline in Sodium at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Sodium at Month 6
Laboratory chemistry sodium
Time frame: Baseline, month 6
Change From Baseline in Sodium at Month 12
Laboratory chemistry sodium
Time frame: Baseline, month 12
Change From Baseline in Phosphorus at Month 1
Laboratory chemistry phosphorus
Time frame: Baseline, month 1
Change From Baseline in Phosphorus at Month 3
Laboratory chemistry phosphorus
Time frame: Baseline, month 3
Change From Baseline in Phosphorus at Month 6
Laboratory chemistry phosphorus
Time frame: Baseline, month 6
Change From Baseline in Phosphorus at Month 12
Change From Baseline in Phosphorus at Month 12
Time frame: Baseline, month 12
Change From Baseline in Total Protein at Month 1
Laboratory chemistry total protein
Time frame: Baseline, month 1
Change From Baseline in Total Protein at Month 3
Laboratory chemistry total protein
Time frame: Baseline, month 3
Change From Baseline in Total Protein at Month 6
Laboratory chemistry total protein
Time frame: Baseline, month 6
Change From Baseline in Total Protein at Month 12
Laboratory chemistry total protein
Time frame: Baseline, month 12
Change From Baseline in Aspartate Amino Transferase at Month 1
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 1
Change From Baseline in Aspartate Amino Transferase at Month 3
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 3
Change From Baseline in Aspartate Amino Transferase
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 6
Change From Baseline in Aspartate Amino Transferase at Month 12
Laboratory chemistry aspartate amino transferase
Time frame: Baseline, month 12
Change From Baseline in Alanine Amino Transferase at Month 1
Laboratory chemistry alanine amino transferase
Time frame: Baseline, month 1
Change From Baseline in Alanine Amino Transferase at Month 3
Laboratory Chemistry alanine amino transferase
Time frame: Baseline, month 3
Change From Baseline in Alanine Amino Transferase at Month 6
Laboratory chemistry alanine amino transferase
Time frame: Baseline, month 6
Change From Baseline in Alanine Amino Transferase at Month 12
Laboratory chemistry alanine amino transferase
Time frame: Baseline, month 12
Change From Baseline in Basophils at Month 1
Laboratory hematology basophils
Time frame: baseline, month 1
Change From Baseline in Basophils at Month 3
Laboratory hematology basophils
Time frame: Baseline, month 3
Change From Baseline in Basophils at Month 6
Laboratory hematology basophils
Time frame: Baseline, month 6
Change From Baseline in Basophils at Month 12
Laboratory hematology basophils
Time frame: Baseline, month 12
Change From Baseline in Eosinophils at Month 1
Laboratory hematology eosinophils
Time frame: Baseline, month 1
Change From Baseline in Eosinophils at Month 3
Laboratory hematology eosinophils
Time frame: Baseline, month 3
Change From Baseline in Eosinophils at Month 6
Laboratory hematology eosinophils
Time frame: Baseline, month 6
Change From Baseline in Eosinophils at Month 12
Laboratory hematology eosinophils
Time frame: Baseline, month 12
Change From Baseline in Hematocrit at Month 1
Laboratory hematology hematocrit
Time frame: Baseline, month 1
Change From Baseline in Hematocrit at Month 3
Laboratory hematology hematocrit
Time frame: Baseline, month 3
Change From Baseline in Hematocrit at Month 6
Laboratory hematology hematocrit
Time frame: Baseline, month 6
Change From Baseline in Hematocrit at Month 12
Laboratory hematology hematocrit
Time frame: Baseline, month 12
Change From Baseline in Hemoglobin at Month 1
Laboratory hematology hemoglobin
Time frame: Baseline, month 1
Change From Baseline in Hemoglobin at Month 3
Laboratory hematology hemoglobin
Time frame: Baseline, month 3
Change From Baseline in Hemoglobin at Month 6
Laboratory hematology hemoglobin
Time frame: Baseline, month 6
Change From Baseline in Hemoglobin at Month 12
Laboratory hematology hemoglobin
Time frame: Baseline, month 12
Change From Baseline in Lymphocytes at Month 1
Laboratory hematology lymphocytes
Time frame: Baseline, month 1
Change From Baseline in Lymphocytes at Month 3
Laboratory hematology lymphocytes
Time frame: Baseline, month 3
Change From Baseline in Lymphocytes at Month 6
Laboratory hematology lymphocytes
Time frame: Baseline, month 6
Change From Baseline in Lymphocytes at Month 12
Laboratory hematology lymphocytes
Time frame: Baseline, month 12
Change From Baseline in Monocytes at Month 1
Laboratory hematology monocytes
Time frame: Baseline, month 1
Change From Baseline in Monocytes at Month 3
Laboratory hematology monocytes
Time frame: Baseline, month 3
Change From Baseline in Monocytes at Month 6
Laboratory hematology monocytes
Time frame: Baseline, month 6
Change From Baseline in Monocytes at Month 12
Laboratory hematology monocytes
Time frame: Baseline, month 12
Change From Baseline in Total Neutrophils at Month 1
Laboratory hematology total neutrophils
Time frame: Baseline, month 1
Change From Baseline in Total Neutrophils at Month 3
Laboratory hematology total neutrophils
Time frame: Baseline, month 3
Change From Baseline in Total Neutrophils at Month 6
Laboratory hematology total neutrophils
Time frame: Baseline, month 6
Change From Baseline in Total Neutrophils at Month 12
Laboratory hematology total neutrophils
Time frame: Baseline, month 12
Change From Baseline in Platelets at Month 1
Laboratory hematology platelets
Time frame: Baseline, month 1
Change From Baseline in Platelets at Month 3
Laboratory hematology platelets
Time frame: Baseline, month 3
Change From Baseline in Platelets at Month 6
Laboratory hematology platelets
Time frame: Baseline, month 6
Change From Baseline in Platelets at Month 12
Laboratory hematology platelets
Time frame: Baseline, month 12
Change From Baseline in Red Blood Cells at Month 1
Laboratory hematology red blood cells
Time frame: Baseline, month 1
Change From Baseline in Red Blood Cells at Month 3
Laboratory hematology red blood cells
Time frame: Baseline, month 3
Change From Baseline in Red Blood Cells at Month 6
Laboratory hematology red blood cells
Time frame: Baseline, month 6
Change From Baseline in Red Blood Cells at Month 12
Laboratory hematology red blood cells
Time frame: Baseline, month 12
Change From Baseline in White Blood Cells at Month 1
Laboratory hematology white blood cells
Time frame: Baseline, month 1
Change From Baseline in White Blood Cells at Month 3
Laboratpry hematology white blood cells
Time frame: Baseline, month 3
Change From Baseline in White Blood Cells at Month 6
Laboratory hematology white blood cells
Time frame: Baseline, month 6
Change From Baseline in White Blood Cells at Month 12
Laboratory hematology white blood cells
Time frame: Baseline, month 12
Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3
Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.
Time frame: Month 1, month 3, month 6, month 12
First Subject Enrolled: 11-Aug-2004 Last Subject Enrolled: 07-Apr-2005
| Milestone | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Started | 76 | 73 | 78 |
| Received investigational product | 72 | 71 | 75 |
| Completed | 39 | 38 | 39 |
| Not completed | 37 | 35 | 39 |
| Withdrew: Physician decision | 9 | 10 | 8 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 15 | 16 | 15 |
| Withdrew: Disease progression | 0 | 1 | 1 |
| Withdrew: Ineligibility determined | 3 | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 |
| Withdrew: Noncompliance | 1 | 0 | 1 |
| Withdrew: Other | 6 | 7 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Requirement for alternative therapy | 1 | 0 | 2 |
Fifteen sites in each wrist and 10 sites in each hand were assessed by a blinded and independent reader. Each site was scored from 0 to 10 (in accordance with the European League Against Rheumatism \[EULAR\]-Outcome Measures in Rheumatology Clinical Trials convention), with each unit increment representing 10% incremental loss of the peripheral 1 cm of articular bone. The Erosion Score is a sum of erosion scores from 50 joint sites in both hands/wrists and ranges from 0 (normal, no erosion) to 500 (worst possible erosion).
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6 | 0.00 ± 3.49 | 0.00 ± 3.43 | 0.49 ± 5.08 |
TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12 | 0 (0 to 1.5) | 0 (-0.5 to 1) | 0.5 (0 to 2) |
TSS is the sum of erosion and joint space narrowing scores obtained from radiographs of the hands and feet, assessed by 2 independent readers. The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280. Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score of 168. The TSS ranged from 0 (normal) to 448 (worst).
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6 | 0 (0 to 0.5) | 0 (0 to 1) | 0 (0 to 1) |
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Radiographic Erosion Score at Month 12 | 0 (0 to 0.5) | 0 (0 to 0.5) | 0 (0 to 1.5) |
The joint erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints in the feet, obtained from radiographs of the hands and feet and assessed by 2 independent readers. Each joint was scored, according to the surface area involved, from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Because each side of a foot joint was graded on this scale, the maximum erosion score for a foot joint was 10 and the maximal erosion score was 280.
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Radiographic Erosion Score at Month 6 | 0 (0 to 0) | 0 (0 to 0.5) | 0 (0 to 0.5) |
Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12 | 0 (0 to 1) | 0 (0 to 0.5) | 0 (0 to 1) |
Joint Space Narrowing (JSN) Score summarizes the severity of JSN in 30 joints of the hands and 12 joints of the feet obtained from radiographs of the hands and feet and assessed by 2 independent readers. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, was scored from 0 (normal JSN) to 4 (complete loss of joint space, bony ankylosis, or luxation), with a maximum JSN score (indicating worst joint space narrowing) of 168.
| units on a scale | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6 | 0 (0 to 0.5) | 0 (0 to 0.97) | 0 (0 to 0.5) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((month 1 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1 | 0.25 ± 0.29 | 0.59 ± 0.29 | -0.34 ± 0.29 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to month 6 calculated using ((month 6 value - baseline value) / baseline value ) x 100. Least squares means are based on a repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6 | 2.61 ± 0.38 | 2.40 ± 0.37 | 0.73 ± 0.38 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 | 4.09 ± 0.40 | 3.00 ± 0.39 | 0.80 ± 0.40 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1 | 0.64 ± 0.38 | -0.15 ± 0.38 | -0.16 ± 0.38 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6 | 0.84 ± 0.37 | 0.89 ± 0.37 | -0.06 ± 0.37 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12 | 1.51 ± 0.47 | 1.34 ± 0.47 | -0.47 ± 0.47 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 1 calculated using ((Month 1 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1 | 0.06 ± 0.22 | 0.00 ± 0.22 | -0.02 ± 0.22 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 6 calculated using ((Month 6 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6 | 1.12 ± 0.24 | 0.95 ± 0.24 | -0.06 ± 0.24 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change from baseline to Month 12 calculated using ((Month 12 value - baseline value) / baseline value ) x 100. Least squares means based on repeated measures model adjusting for treatment, visit, baseline value, and strata (4 strata from the combination of baseline use of steroid and previous use of biologic).
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12 | 1.67 ± 0.33 | 1.56 ± 0.33 | -0.38 ± 0.33 |
Percent change from baseline to Month 3 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3 | -78.67 (-86.29 to -62.86) | -80.46 (-86.27 to -66.84) | -11.48 (-26.95 to 15.59) |
Percent change from baseline to Month 6 in serum Collagen C-Telopeptide (CTX) Type I calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Serum CTX at Month 6 | -62.69 (-78.56 to -46.23) | -50.64 (-63.31 to -22.37) | -12.94 (-31.20 to 23.30) |
Percent change from Baseline to Month 12 in serum C-Telopeptide (CTX) Type I calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Serum CTX at Month 12 | -65.65 (-78.62 to -48.40) | -47.24 (-63.60 to -27.20) | -23.36 (-45.43 to 1.67) |
Percent change from baseline to Month 3 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3 | -55.08 (-69.30 to -44.40) | -57.57 (-70.07 to -46.07) | -12.23 (-21.57 to -0.11) |
Percent change from baseline to Month 6 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in P1NP at Month 6 | -57.06 (-67.17 to -37.13) | -51.57 (-64.51 to -37.35) | -22.17 (-39.69 to -3.07) |
Percent change from baseline to Month 12 in procollagen 1 N-terminal peptide (P1NP) calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in P1NP at Month 12 | -45.84 (-61.36 to -30.09) | -41.8 (-57.30 to -18.89) | -17.53 (-31.42 to -0.02) |
Percent change from baseline to Month 3 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 3 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3 | -46.59 (-71.58 to 4.17) | -35.8 (-56.80 to 16.99) | 2.71 (-24.18 to 31.72) |
Percent change from baseline to Month 6 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 6 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6 | 7.17 (-32.43 to 88.27) | 9.65 (-21.79 to 51.16) | 4.54 (-27.44 to 56.52) |
Percent change from baseline to Month 12 in urine Type II collagen C-Telopeptide (CTX)/Creatinine calculated using ((Month 12 value - Baseline value) / Baseline value ) x 100.
| Percent change from baseline | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12 | 36.92 (4.50 to 111.51) | 61.92 (-15.84 to 108.60) | -3.93 (-37.70 to 126.65) |
Serum from participants was tested for antibodies to denosumab by immuoassay at months 1, 3, 6 and 12. The number of participants with anti-denosumab antibodies at any assessment is reported.
| Participants | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Number of Participants With Anti-Denosumab Binding Antibodies | 4 | 0 | 2 |
Serum from participants testing positive for anti-denosumab binding antibodies was tested in a cell-based bioassay for neutralizing activity against denosumab.
| Participants | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody | 0 | — | 0 |
Laboratory Chemistry Albumin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Albumin at Month 1 | -0.36 ± 2.29 | -0.24 ± 2.25 | -0.30 ± 2.21 |
Laboratory chemistry albumin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Albumin at Month 3 | -0.30 ± 2.18 | -0.12 ± 2.28 | -0.18 ± 2.07 |
Laboratory chemistry albumin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Albumin at Month 6 | -0.30 ± 2.49 | -0.90 ± 2.56 | -0.77 ± 2.40 |
Laboratory chemistry albumin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Albumin at Month 12 | -0.13 ± 2.41 | -0.06 ± 2.26 | -0.59 ± 2.49 |
Laboratory chemistry alkaline phoshatatse
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alkaline Phosphatase at Month 1 | -5.87 ± 10.52 | -3.66 ± 11.97 | 1.18 ± 15.62 |
Laboratory chemisrty alkaline phosphatase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alkaline Phosphatase at Month 3 | -13.27 ± 15.91 | -12.38 ± 13.09 | -2.03 ± 8.37 |
Laboratory chemistry alkaline phosphatase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alkaline Phosphatase at Month 6 | -7.84 ± 31.94 | -12.49 ± 12.61 | -0.54 ± 18.46 |
Laboratory chemistry alkaline phosphatase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alkaline Phosphatase at Month 12 | -11.92 ± 16.74 | -11.34 ± 18.18 | -4.63 ± 16.70 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Bicarbonate at Month 1 | 0.78 ± 2.31 | 0.06 ± 3.06 | 0.54 ± 2.94 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Bicarbonate at Month 3 | 0.12 ± 2.40 | 0.39 ± 2.84 | -0.67 ± 3.17 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Bicarbonate at Month 6 | 0.45 ± 2.29 | -0.12 ± 2.61 | -0.18 ± 2.67 |
Laboratory chemistry bicarbonate
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Bicarbonate at Month 12 | 0.81 ± 2.12 | 0.58 ± 2.68 | 0.23 ± 2.50 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Bilirubin at Month 1 | 0.26 ± 2.39 | -0.23 ± 2.45 | 0.42 ± 2.83 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Bilirubin at Month 3 | 0.92 ± 2.17 | -0.23 ± 2.36 | 0.44 ± 2.74 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Bilirubin at Month 6 | 1.08 ± 2.58 | -0.61 ± 2.49 | 0.34 ± 3.30 |
Laboratory chemistry total bilirubin
| umol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Bilirubin at Month 12 | 0.41 ± 2.58 | -0.35 ± 2.28 | 0.03 ± 2.80 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Blood Urea Nitrogen at Month 1 | 0 ± 1.35 | 0.15 ± 1.40 | -0.01 ± 1.55 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Blood Urea Nitrogen at Month 3 | 0.04 ± 1.35 | 0.41 ± 1.59 | 0.06 ± 1.43 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Blood Urea Nitrogen at Month 6 | -0.21 ± 1.44 | -0.08 ± 1.41 | -0.04 ± 2.29 |
Laboratory chemistry blood urea nitrogen
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Blood Urea Nitrogen at Month 12 | 0.32 ± 1.37 | 0.24 ± 1.46 | -0.09 ± 1.56 |
Laboratory chemistry calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium at Month 1 | -0.05 ± 0.11 | -0.05 ± 0.09 | 0.01 ± 0.09 |
Laboratory chemistry calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium at Month 3 | -0.01 ± 0.11 | -0.02 ± 0.10 | 0 ± 0.10 |
Laboratory chemistry calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium at Month 6 | -0.01 ± 0.10 | -0.03 ± 0.11 | -0.01 ± 0.10 |
Laboratory chemistry calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium at Month 12 | -0.01 ± 0.11 | 0.01 ± 0.09 | 0.01 ± 0.08 |
Laboratory chemistry albumin-adjusted calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium (Corrected) at Month 1 | -0.05 ± 0.11 | -0.05 ± 0.09 | 0.01 ± 0.09 |
Laboratory chemistry albumin-adjusted calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium (Corrected) at Month 3 | -0.01 ± 0.11 | -0.02 ± 0.09 | 0 ± 0.10 |
Laboratory chemistry albumin-adjusted calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium (Corrected) at Month 6 | -0.01 ± 0.10 | -0.02 ± 0.10 | -0.01 ± 0.09 |
Laboratory chemistry albumin-adjusted calcium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Calcium (Corrected) at Month 12 | -0.01 ± 0.11 | 0.01 ± 0.09 | 0 ± 0.08 |
Laboratory chemistry chloride
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Chloride at Month 1 | 0.24 ± 2.36 | 0.58 ± 2.66 | 0.01 ± 2.09 |
Laboratory chemistry chloride
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Chloride at Month 3 | -0.01 ± 2.67 | 0.38 ± 2.35 | 0.78 ± 2.20 |
Laboratory chemistry chloride
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Chloride at Month 6 | -0.57 ± 2.85 | 0.48 ± 2.19 | 0 ± 2.79 |
Laboratory chemistry chloride
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Chloride at Month 12 | -0.62 ± 2.45 | -0.21 ± 2.58 | -0.08 ± 2.39 |
Laboratory chemistry creatinine
| µmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Creatinine at Month 1 | -0.88 ± 9.89 | 0.38 ± 8.63 | 1.47 ± 8.78 |
Laboratory chemistry creatinine
| µmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Creatinine at Month 3 | 0.62 ± 11.11 | 3.20 ± 8.30 | 3.81 ± 9.24 |
Laboratory chemistry creatinine
| µmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Creatinine at Month 6 | 3.30 ± 10.97 | 3.84 ± 9.88 | 3.54 ± 11.60 |
Laboratory chemistry creatinine
| µmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Creatinine at Month 12 | 5.44 ± 10.09 | 4.42 ± 9.59 | 3.73 ± 7.84 |
Laboratory chemistry gamma-glutamyl transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gamma-Glutamyl Transferase at Month 1 | 1.04 ± 8.13 | -1.25 ± 9.67 | 0.26 ± 10.63 |
Laboratory chemistry gamma-glutamyl transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gamma-Glutamyl Transferase at Month 3 | 2.32 ± 10.94 | 0.04 ± 9.90 | 1.51 ± 15.87 |
Laboratory chemistry gamma-glutamyl transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gamma-Glutamyl Transferase at Month 6 | 7.37 ± 36.42 | 0.28 ± 12.70 | 5.67 ± 37.98 |
Laboratory chemistry gamma-glutamyl transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gamma-Glutamyl Transferase at Month 12 | 2.98 ± 10.94 | 1.08 ± 16.09 | -1.38 ± 14.70 |
Laboratory chemistry glucose
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Glucose at Month 1 | 0.06 ± 0.76 | 0.20 ± 0.65 | 0.05 ± 1.28 |
Laboratory chemistry glucose
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Glucose at Month 3 | 0.08 ± 0.87 | 0.20 ± 0.63 | 0.04 ± 1.26 |
Laboratory chemistry glucose
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Glucose at Month 6 | 0.12 ± 0.85 | 0.20 ± 0.65 | -0.05 ± 1.26 |
Laboratory chemistry glucose
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Glucose at Month 12 | -0.04 ± 0.66 | 0.22 ± 0.96 | 0.19 ± 1.27 |
Laboratory chemistry potassium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Potassium at Month 1 | 0.06 ± 0.38 | 0.06 ± 0.36 | 0.04 ± 0.36 |
Laboratory chemistry potassium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Potassium at Month 3 | -0.01 ± 0.39 | 0.06 ± 0.40 | 0.04 ± 0.38 |
Laboratory chemistry potassium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Potassium at Month 6 | 0.01 ± 0.44 | -0.01 ± 0.36 | 0 ± 0.42 |
Laboratory chemistry potassium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Potassium at Month 12 | -0.07 ± 0.44 | -0.08 ± 0.35 | -0.04 ± 0.43 |
Laboratory chemistry magnesium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Magnesium at Month 1 | 0.01 ± 0.06 | 0.02 ± 0.06 | 0.01 ± 0.05 |
Laboratory chemistry magnesium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Magnesium at Month 3 | -0.01 ± 0.06 | 0.02 ± 0.06 | 0 ± 0.06 |
Laboratory chemistry magnesium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Magnesium at Month 6 | 0 ± 0.06 | 0.01 ± 0.06 | 0.01 ± 0.07 |
Laboratory chemistry magnesium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Magnesium at Month 12 | -0.01 ± 0.06 | -0.01 ± 0.07 | -0.01 ± 0.08 |
Laboratory chemistry sodium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sodium at Month 1 | -0.03 ± 1.93 | -0.06 ± 2.62 | 0.33 ± 2.03 |
Change From Baseline in Sodium at Month 3
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sodium at Month 3 | -0.14 ± 2.13 | -0.16 ± 2.29 | 0.39 ± 2.38 |
Laboratory chemistry sodium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sodium at Month 6 | -0.12 ± 1.98 | -0.06 ± 1.75 | 0.03 ± 2.27 |
Laboratory chemistry sodium
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sodium at Month 12 | -0.25 ± 2.02 | -0.27 ± 2.75 | 0.33 ± 2.38 |
Laboratory chemistry phosphorus
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Phosphorus at Month 1 | -0.09 ± 0.16 | -0.06 ± 0.19 | 0.02 ± 0.14 |
Laboratory chemistry phosphorus
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Phosphorus at Month 3 | -0.03 ± 0.16 | -0.03 ± 0.18 | 0.01 ± 0.20 |
Laboratory chemistry phosphorus
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Phosphorus at Month 6 | -0.05 ± 0.17 | -0.01 ± 0.18 | 0.03 ± 0.19 |
Change From Baseline in Phosphorus at Month 12
| mmol/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Phosphorus at Month 12 | -0.05 ± 0.17 | 0 ± 0.17 | 0 ± 0.16 |
Laboratory chemistry total protein
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Protein at Month 1 | -0.46 ± 3.56 | -0.40 ± 3.22 | 0.21 ± 3.00 |
Laboratory chemistry total protein
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Protein at Month 3 | -0.29 ± 3.35 | 0.07 ± 3.42 | -0.20 ± 3.54 |
Laboratory chemistry total protein
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Protein at Month 6 | -0.09 ± 4.13 | -0.62 ± 3.40 | -0.57 ± 3.19 |
Laboratory chemistry total protein
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Protein at Month 12 | -0.97 ± 3.76 | -0.91 ± 3.55 | -0.98 ± 3.10 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Aspartate Amino Transferase at Month 1 | -0.79 ± 5.84 | -0.26 ± 8.14 | 0.90 ± 8.35 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Aspartate Amino Transferase at Month 3 | 1.99 ± 5.77 | 0.40 ± 8.78 | 2.69 ± 9.37 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Aspartate Amino Transferase | 3.85 ± 15.66 | 0.87 ± 7.58 | 3.24 ± 15.90 |
Laboratory chemistry aspartate amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Aspartate Amino Transferase at Month 12 | 3.86 ± 18.62 | 3.75 ± 18.11 | 2.24 ± 7.32 |
Laboratory chemistry alanine amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alanine Amino Transferase at Month 1 | -1.84 ± 8.61 | -1.03 ± 12.37 | 1.20 ± 15.44 |
Laboratory Chemistry alanine amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alanine Amino Transferase at Month 3 | 0.04 ± 8.85 | -2.10 ± 14.34 | 1.54 ± 13.00 |
Laboratory chemistry alanine amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alanine Amino Transferase at Month 6 | 1.20 ± 15.83 | -1.76 ± 14.12 | 5.44 ± 51.19 |
Laboratory chemistry alanine amino transferase
| U/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alanine Amino Transferase at Month 12 | 4.86 ± 24.46 | 1.66 ± 14.30 | 1.82 ± 14.41 |
Laboratory hematology basophils
| *10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Basophils at Month 1 | 0 ± 0.07 | 0 ± 0.07 | -0.01 ± 0.07 |
Laboratory hematology basophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Basophils at Month 3 | -0.01 ± 0.06 | -0.01 ± 0.07 | -0.01 ± 0.07 |
Laboratory hematology basophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Basophils at Month 6 | 0 ± 0.06 | 0 ± 0.07 | 0 ± 0.06 |
Laboratory hematology basophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Basophils at Month 12 | 0.02 ± 0.09 | 0 ± 0.09 | 0.03 ± 0.07 |
Laboratory hematology eosinophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Eosinophils at Month 1 | -0.02 ± 0.09 | -0.01 ± 0.09 | 0.01 ± 0.08 |
Laboratory hematology eosinophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Eosinophils at Month 3 | 0 ± 0.10 | 0 ± 0.10 | -0.01 ± 0.09 |
Laboratory hematology eosinophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Eosinophils at Month 6 | -0.03 ± 0.09 | 0 ± 0.13 | 0 ± 0.13 |
Laboratory hematology eosinophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Eosinophils at Month 12 | 0.03 ± 0.16 | 0.02 ± 0.12 | 0.01 ± 0.12 |
Laboratory hematology hematocrit
| Proportion of red blood cells in blood | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hematocrit at Month 1 | 0 ± 0.02 | 0 ± 0.02 | 0 ± 0.02 |
Laboratory hematology hematocrit
| Proportion of red blood cells in blood | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hematocrit at Month 3 | 0.01 ± 0.02 | 0 ± 0.03 | 0 ± 0.03 |
Laboratory hematology hematocrit
| Proportion of red blood cells in blood | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hematocrit at Month 6 | 0.01 ± 0.02 | 0 ± 0.03 | 0 ± 0.03 |
Laboratory hematology hematocrit
| Proportion of red blood cells in blood | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hematocrit at Month 12 | 0 ± 0.02 | 0 ± 0.03 | -0.01 ± 0.03 |
Laboratory hematology hemoglobin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin at Month 1 | -0.33 ± 6.73 | -1.48 ± 6.39 | -0.69 ± 6.34 |
Laboratory hematology hemoglobin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin at Month 3 | 0.69 ± 7.02 | -1.02 ± 8.36 | -1.10 ± 6.30 |
Laboratory hematology hemoglobin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin at Month 6 | -0.36 ± 7.80 | -1.69 ± 8.82 | -0.69 ± 8.21 |
Laboratory hematology hemoglobin
| g/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin at Month 12 | 1.21 ± 9.26 | 0.02 ± 11.66 | -0.46 ± 10.08 |
Laboratory hematology lymphocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Lymphocytes at Month 1 | -0.02 ± 0.41 | 0.10 ± 0.40 | 0 ± 0.45 |
Laboratory hematology lymphocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Lymphocytes at Month 3 | 0.07 ± 0.38 | 0.14 ± 0.48 | 0.08 ± 0.46 |
Laboratory hematology lymphocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Lymphocytes at Month 6 | 0.12 ± 0.41 | 0.05 ± 0.35 | 0.03 ± 0.68 |
Laboratory hematology lymphocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Lymphocytes at Month 12 | -0.02 ± 0.49 | 0.04 ± 0.50 | -0.02 ± 0.49 |
Laboratory hematology monocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Monocytes at Month 1 | 0.01 ± 0.13 | -0.01 ± 0.10 | 0.01 ± 0.12 |
Laboratory hematology monocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Monocytes at Month 3 | 0.02 ± 0.11 | 0.01 ± 0.11 | 0.02 ± 0.11 |
Laboratory hematology monocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Monocytes at Month 6 | 0.05 ± 0.17 | 0.04 ± 0.12 | 0.04 ± 0.13 |
Laboratory hematology monocytes
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Monocytes at Month 12 | 0.03 ± 0.15 | 0 ± 0.11 | 0.02 ± 0.13 |
Laboratory hematology total neutrophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Neutrophils at Month 1 | 0 ± 1.97 | 0.18 ± 1.99 | -0.13 ± 1.68 |
Laboratory hematology total neutrophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Neutrophils at Month 3 | 0.11 ± 1.92 | 0.26 ± 1.64 | -0.11 ± 1.55 |
Laboratory hematology total neutrophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Neutrophils at Month 6 | 0.18 ± 1.67 | -0.05 ± 1.66 | 0.27 ± 2.36 |
Laboratory hematology total neutrophils
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Neutrophils at Month 12 | 0.65 ± 2.37 | 0.04 ± 1.79 | 0.10 ± 2.31 |
Laboratory hematology platelets
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Platelets at Month 1 | 1.78 ± 44.53 | 10.36 ± 49.34 | 2.96 ± 44.15 |
Laboratory hematology platelets
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Platelets at Month 3 | -2.82 ± 48.86 | 6.86 ± 50.18 | -1.97 ± 45.94 |
Laboratory hematology platelets
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Platelets at Month 6 | 1.95 ± 54.95 | 1.00 ± 45.64 | 1.57 ± 53.39 |
Laboratory hematology platelets
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Platelets at Month 12 | 3.32 ± 51.66 | -4.26 ± 51.12 | 1.07 ± 58.16 |
Laboratory hematology red blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Red Blood Cells at Month 1 | -0.01 ± 0.21 | -0.01 ± 0.20 | -0.01 ± 0.19 |
Laboratory hematology red blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Red Blood Cells at Month 3 | 0.05 ± 0.23 | 0.02 ± 0.28 | 0 ± 0.23 |
Laboratory hematology red blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Red Blood Cells at Month 6 | 0.01 ± 0.24 | -0.04 ± 0.26 | 0.01 ± 0.26 |
Laboratory hematology red blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Red Blood Cells at Month 12 | 0.01 ± 0.27 | -0.06 ± 0.30 | -0.03 ± 0.29 |
Laboratory hematology white blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in White Blood Cells at Month 1 | -0.03 ± 2.07 | 0.26 ± 2.04 | -0.10 ± 1.88 |
Laboratpry hematology white blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in White Blood Cells at Month 3 | 0.18 ± 1.93 | 0.40 ± 1.71 | -0.05 ± 1.64 |
Laboratory hematology white blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in White Blood Cells at Month 6 | 0.30 ± 1.78 | 0.04 ± 1.85 | 0.35 ± 2.34 |
Laboratory hematology white blood cells
| * 10^9/L | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Change From Baseline in White Blood Cells at Month 12 | 0.70 ± 2.40 | 0.11 ± 1.86 | 0.13 ± 2.22 |
Participants with laboratory toxicity of grade 3 or 4, graded according to the Common Terminology Criteria for Adverse Events, version 3.0, on the following general guideline: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death related to AE.
| Participants | Denosumab 180 mg | Denosumab 60 mg | Placebo |
|---|---|---|---|
| Alanine Amino Transferase-above normal (grade 3) | 0 | 0 | 1 |
| Aspartate Amino Transferase-above normal (grade 3) | 0 | 1 | 0 |
| Glucose-above normal (grade 3) | 1 | 0 | 0 |
| Lymphocytes-below normal (grade 3) | 1 | 3 | 2 |
| Sodium-below normal (grade 3) | 1 | 2 | 0 |
| White Blood Cells-below normal (grade 3) | 0 | 1 | 1 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/75 (6.7%) | 47/75 (62.7%) |
| Denosumab 60 mg | — | 3/71 (4.2%) | 44/71 (62%) |
| Denosumab 180 mg | — | 6/72 (8.3%) | 44/72 (61.1%) |
| Event | Placebo | Denosumab 60 mg | Denosumab 180 mg |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/75 | 1/71 | 0/72 |
| CellulitisInfections and infestations | 0/75 | 1/71 | 0/72 |
| Humerus fractureInjury, poisoning and procedural complications | 0/75 | 1/71 | 0/72 |
| Thermal burnInjury, poisoning and procedural complications | 0/75 | 1/71 | 0/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/75 | 1/71 | 0/72 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 1/71 | 0/72 |
| Transient ischaemic attackNervous system disorders | 0/75 | 1/71 | 0/72 |
| AnaemiaBlood and lymphatic system disorders | 0/75 | 0/71 | 1/72 |
| Coronary artery diseaseCardiac disorders | 0/75 | 0/71 | 1/72 |
| PyelonephritisInfections and infestations | 0/75 | 0/71 | 1/72 |
| Event | Placebo | Denosumab 60 mg | Denosumab 180 mg |
|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 24/75 | 22/71 | 21/72 |
| Upper respiratory tract infectionInfections and infestations | 6/75 | 11/71 | 8/72 |
| NasopharyngitisInfections and infestations | 9/75 | 5/71 | 5/72 |
| SinusitisInfections and infestations | 8/75 | 4/71 | 8/72 |
| FatigueGeneral disorders | 3/75 | 6/71 | 0/72 |
| InfluenzaInfections and infestations | 0/75 | 2/71 | 6/72 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/75 | 5/71 | 1/72 |
| Urinary tract infectionInfections and infestations | 1/75 | 4/71 | 3/72 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/75 | 4/71 | 2/72 |
| BronchitisInfections and infestations | 3/75 | 3/71 | 4/72 |
| Age, Continuous(Years) | Denosumab 180 mg | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 58 ± 11 | 57.3 ± 11.4 | 57 ± 11.1 | 57.4 ± 11.2 |
| Sex: Female, Male(Participants) | Denosumab 180 mg | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 53 | 51 | 62 | 166 |
| Male | 23 | 22 | 16 | 61 |
| Race/Ethnicity, Customized(Participants) | Denosumab 180 mg | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|---|
| Asian | 1 | 1 | 2 | 4 |
| Japanese | 1 | 0 | 1 | 2 |
| American Indian or Alaska Native | 1 | 2 | 1 | 4 |
| White or Caucasian | 66 | 59 | 62 | 187 |
| Black or African American | 1 | 3 | 2 | 6 |
| Hispanic or Latino | 6 | 6 | 9 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Other | 0 | 2 | 0 | 2 |
No study locations are listed for this record.
Ran from Aug 2004 to primary completion in Apr 2007, 31 months.
Results were first posted in Jan 2014, 6 years 9 months after primary completion. A results delay was requested in Nov 2009.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 31 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab